Core Viewpoint - Boston Scientific Corporation (BSX) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of 75 cents, a 33.9% increase year-over-year, surpassing both the Zacks Consensus Estimate and the company's own guidance range [1][3][11] Financial Performance - The first-quarter revenue reached $4.66 billion, reflecting a 20.9% year-over-year increase on a reported basis and 22.2% on an operational basis, exceeding the Zacks Consensus Estimate by 2.3% [3][11] - Reported EPS for the quarter was 45 cents, marking a 36.4% increase from the previous year [2] Revenue Breakdown - Revenue growth by region included a 31.1% increase in the United States, 5.5% in EMEA, 8.2% in Asia Pacific, and 4.4% in Latin America and Canada [4] - Emerging markets saw a reported revenue growth of 6.5% [4] Segment Performance - MedSurg segment revenues were $1.58 billion, up 11.7% year-over-year, with notable contributions from Endoscopy ($673 million), Urology ($633 million), and Neuromodulation ($271 million) [6] - Cardiovascular segment revenues reached $3.09 billion, a 26.2% increase, with Cardiology business sales totaling $2.43 billion, up 31.2% [7] Margin Analysis - Gross margin expanded by 19 basis points to 68.8%, while adjusted operating margin increased by 127 basis points to 24.8% [8] Future Outlook - For 2025, BSX anticipates net sales growth of approximately 15-17% on a reported basis and 12-14% on an organic basis, with adjusted EPS expected in the range of $2.87-$2.94 [9][10] - The second quarter of 2025 is projected to see revenue growth of 17.5-19.5% on a reported basis [10] Strategic Developments - Recent acquisitions include SoniVie Ltd. and Bolt Medical, which are expected to positively impact the company's growth trajectory [12]

Core Insights - Boston Scientific reported revenue of $4.66 billion for the quarter ended March 2025, reflecting a year-over-year increase of 20.9% and surpassing the Zacks Consensus Estimate of $4.56 billion by 2.31% [1] - The company's EPS for the quarter was $0.75, an increase from $0.56 in the same quarter last year, exceeding the consensus EPS estimate of $0.67 by 11.94% [1] Financial Performance - Geographic Revenue from the U.S. was $2.96 billion, exceeding the average estimate of $2.86 billion and showing a year-over-year growth of 31.1% [4] - Revenue from the Rest of the World was reported at $1.70 billion, matching the average estimate from analysts [4] - Net Sales in Cardiovascular- Worldwide reached $3.09 billion, surpassing the average estimate of $2.96 billion and representing a 26.2% year-over-year increase [4] - Net Sales in MedSurg- Worldwide totaled $1.58 billion, slightly below the average estimate of $1.59 billion, but still reflecting an 11.7% increase compared to the previous year [4] Segment Performance - Cardiovascular- Cardiology- Worldwide sales were $2.43 billion, exceeding the estimated $2.31 billion and showing a 29.8% year-over-year growth [4] - MedSurg- Neuromodulation- Worldwide reported sales of $271 million, above the average estimate of $266.87 million, with a year-over-year increase of 5.9% [4] - Cardiovascular- Peripheral Interventions- Worldwide sales were $656 million, slightly below the average estimate of $658.51 million, but still reflecting a 14.5% year-over-year increase [4] Stock Performance - Over the past month, Boston Scientific shares have returned -7.8%, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Boston Scientific Corporation announces the retirement of Dan Brennan, the executive vice president and chief financial officer, after nearly 30 years with the company, effective at the end of June 2025, with a transition period as a senior advisor until early October 2025 [1][2] Company Leadership Transition - Jon Monson, currently senior vice president of Investor Relations, will succeed Dan Brennan as executive vice president and CFO, effective June 30, 2025, reporting to CEO Mike Mahoney [2][3] - Brennan and Monson will collaborate closely to ensure a smooth transition, with Monson taking on responsibilities including global controllership, corporate finance, and corporate business development [2][3] Dan Brennan's Contributions - Dan Brennan has been recognized for his exceptional leadership and contributions to Boston Scientific, particularly in transforming the company's financial performance and developing talent within the financial organization [2][3] - Under Brennan's leadership since 2014, the company has overseen numerous strategic investment opportunities [2] Jon Monson's Background - Jon Monson has over 25 years of experience with Boston Scientific, having held various roles in finance, including global controller and chief accounting officer [3] - He is a certified public accountant with a Bachelor of Arts degree in economics and accounting from the College of the Holy Cross [3] Company Overview - Boston Scientific is a global leader in medical technology, providing innovative solutions to improve patient health and reduce healthcare costs [4] - The company has been advancing science for life for over 45 years, offering a wide range of devices and therapies for various medical conditions [4]

Financial Performance - Boston Scientific reported net sales of $4.663 billion for Q1 2025, a 20.9% increase on a reported basis, 22.2% on an operational basis, and 18.2% on an organic basis compared to the prior year[1][3]. - GAAP net income attributable to common stockholders was $674 million, or $0.45 per share, compared to $495 million, or $0.33 per share a year ago; adjusted EPS was $0.75, up from $0.56[1][3]. - Net sales for Q1 2025 reached $4,663 million, a 21% increase from $3,856 million in Q1 2024[21]. - Gross profit for Q1 2025 was $3,210 million, up from $2,648 million in Q1 2024, reflecting a gross margin improvement[21]. - Operating income increased to $921 million in Q1 2025, compared to $675 million in Q1 2024, representing a 36% growth[21]. - Net income attributable to Boston Scientific common stockholders for Q1 2025 was $674 million, a 36% increase from $495 million in Q1 2024[21]. - Basic net income per share for Q1 2025 was $0.46, up from $0.34 in Q1 2024, indicating a 35% increase[21]. - Adjusted net income for Q1 2025 was $1,121 million, compared to $832 million in Q1 2024, reflecting a significant increase[23]. Sales Growth - The Cardiovascular segment achieved a reported sales growth of 26.2%, while MedSurg grew by 11.7% compared to the prior year[3]. - U.S. sales increased by 31.1% to $2.96 billion, while EMEA and APAC regions saw growth of 5.5% and 8.2%, respectively[9]. - Full year 2025 net sales growth is estimated to be approximately 15% to 17% on a reported basis and 12% to 14% on an organic basis[11]. - For Q2 2025, the company expects net sales growth in the range of 17.5% to 19.5% on a reported basis and 13% to 15% on an organic basis[12]. - The company expects Q2 2025 net sales growth to be between 17.5% and 19.5%, with full-year growth estimated at 15.0% to 17.0%[27]. - Organic growth for Q2 2025 is projected to be between 13.0% and 15.0%, and for the full year, it is expected to be between 12.0% and 14.0%[27]. Research and Development - The company plans to continue investing in research and development, with R&D expenses increasing to $443 million in Q1 2025 from $366 million in Q1 2024[21]. Acquisitions and Clinical Trials - Boston Scientific completed the acquisition of Bolt Medical, Inc., and announced an agreement to acquire SoniVie Ltd., focusing on innovative medical technologies[7]. - The company commenced enrollment in the ELEVATE-PF clinical trial for the FARAFLEX™ Mapping and Pulsed Field Ablation Catheter targeting persistent atrial fibrillation[7]. Product Performance - The FARAPULSE™ PFA System demonstrated superior effectiveness in treating symptomatic paroxysmal atrial fibrillation compared to Medtronic's Arctic Front Advance™ catheter[7]. Operational Challenges - Boston Scientific is focusing on operational growth while managing the impact of acquisitions and divestitures, which is expected to affect growth rates negatively by approximately 4.5% in Q2 2025[27].

MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, ...

近日，思宇MedTech注意到波士顿科学的一则招聘信息：房颤解决方案事业部启动"百岗校招"计划， 面向2025届应届生及毕业两年内的候选人，开放150 个临床技术培训生岗位，覆盖全国34个省市。 与以往偏向市场、销售类岗位的招聘不同，此次的重点落在了被业内称为"跟台岗"的 临床一线技术支持人员 。根据招聘描述，新入职者将直接参与房颤治 疗手术全过程，包括术前准备、术中支持及术后沟通。换句话说，他们从培训结束后就能站上手术现场，服务于真实病例和真实操作。 这看上去不仅是一轮简单的人才扩充，更是波士顿科学在中国房颤市场加速深化临床部署、全面提升一线渗透力的重要举措。 2024年，波士顿科学的 FARAPULSE脉冲电场消融系统 获得国家药品监督管理局（NMPA）批准，成为国内首款进口PFA系统。同时，其在房颤卒中预防 方向上的代表产品—— Watchman左心耳封堵系统 ——也在中国进入成熟应用期。 在思宇看来，这场校招，是波士顿科学"重投临床、深耕一线"战略思路的具体体现。通过年轻技术人才的广泛铺设，波士顿科学或将打通产品—术式—医院 —医生之间的落地通路，为房颤整体解决方案在中国的本地化放量奠定基础。 一、房 ...

近日，思宇MedTech注意到波士顿科学的一则招聘信息：房颤解决方案事业部启动"百岗校招"计划， 面向2025届应届生及毕业两年内的候选人，开放150 个临床技术培训生岗位，覆盖全国34个省市。 与以往偏向市场、销售类岗位的招聘不同，此次的重点落在了被业内称为"跟台岗"的 临床一线技术支持人员 。根据招聘描述，新入职者将直接参与房颤治 疗手术全过程，包括术前准备、术中支持及术后沟通。换句话说，他们从培训结束后就能站上手术现场，服务于真实病例和真实操作。 这看上去不仅是一轮简单的人才扩充，更是波士顿科学在中国房颤市场加速深化临床部署、全面提升一线渗透力的重要举措。 2024年，波士顿科学的 FARAPULSE脉冲电场消融系统 获得国家药品监督管理局（NMPA）批准，成为国内首款进口PFA系统。同时，其在房颤卒中预防 方向上的代表产品—— Watchman左心耳封堵系统 ——也在中国进入成熟应用期。 在思宇看来，这场校招，是波士顿科学"重投临床、深耕一线"战略思路的具体体现。通过年轻技术人才的广泛铺设，波士顿科学或将打通产品—术式—医院 —医生之间的落地通路，为房颤整体解决方案在中国的本地化放量奠定基础。 一、房 ...

Core Viewpoint - Boston Scientific (BSX) is expected to report first-quarter 2025 results on April 23, projecting adjusted earnings between 66-68 cents per share and revenue growth of approximately 17-19% on a reported basis, with organic growth of 14-16% [1] Financial Performance - The Zacks Consensus Estimate for earnings is steady at 67 cents per share, indicating a 19.6% growth from the previous year [2] - BSX has beaten the Zacks Consensus Estimate in the last four quarters, with an average earnings surprise of 8.25% [2] Earnings Expectations - Boston Scientific has an Earnings ESP of 0.00%, indicating a lower chance of beating estimates [3] - The company currently holds a Zacks Rank 3 (Hold) [3] Business Growth Factors - The company experienced above-market growth across all business units in 2024, with expectations of continued momentum in Q1 2025, driven by demand in Electrophysiology and strong global franchises [4] - Asia-Pacific, particularly Japan and China, is expected to perform well, with Japan benefiting from the adoption of AGENT DCB and China projected to grow in the mid-teens despite pricing headwinds [5] Profitability Challenges - Profitability may remain sluggish due to a challenging supply environment, tariff complications, rising labor and raw material costs, and healthcare staffing shortages [6] Segment Performance - The WATCHMAN subsegment is expected to show strong growth, with a consensus revenue estimate of $408.6 million for Q1, reflecting a 16.5% increase year-over-year [8] - Interventional Cardiology is projected to see steady growth, with estimated revenues of $678 million, a 3.9% improvement [9] - Peripheral Interventions are expected to generate $659 million in revenues, indicating a 15% increase [10] - Interventional Oncology and Urology/Pelvic Health are anticipated to show strong growth due to robust product offerings [11] Stock Performance - BSX stock has gained 41.6% over the past year, outperforming its industry and peers like Abbott and Medtronic [14] - The Wall Street average price target for BSX is $118.29 per share, suggesting a 24.2% upside from current levels [19] Valuation Concerns - BSX has a Value Score of D, indicating a stretched valuation, with a forward P/E ratio of 32.19 compared to the industry average of 20.45 [17] - Current shareholders are advised to hold, while new investors may consider waiting for a better entry point [23]

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.67 per share, indicating an increase of 19.6% compared to the year-ago period. Analysts forecast revenues of $4.56 billion, representing an increase of 18.2% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclos ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that t ...